DE3048039A1 - "pharmazeutische zusammensetzungen" - Google Patents
"pharmazeutische zusammensetzungen"Info
- Publication number
- DE3048039A1 DE3048039A1 DE19803048039 DE3048039A DE3048039A1 DE 3048039 A1 DE3048039 A1 DE 3048039A1 DE 19803048039 DE19803048039 DE 19803048039 DE 3048039 A DE3048039 A DE 3048039A DE 3048039 A1 DE3048039 A1 DE 3048039A1
- Authority
- DE
- Germany
- Prior art keywords
- mixture
- cefalexin
- weight
- lubricant
- silicon dioxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 58
- 239000002775 capsule Substances 0.000 claims description 41
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 37
- 229940106164 cephalexin Drugs 0.000 claims description 37
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 35
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 239000000314 lubricant Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 8
- 239000008119 colloidal silica Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 7
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 4
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000005429 filling process Methods 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940081090 cefa Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7944279 | 1979-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3048039A1 true DE3048039A1 (de) | 1981-09-10 |
Family
ID=10510032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19803048039 Withdrawn DE3048039A1 (de) | 1979-12-21 | 1980-12-19 | "pharmazeutische zusammensetzungen" |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS5699415A (enExample) |
| BE (1) | BE886778A (enExample) |
| DE (1) | DE3048039A1 (enExample) |
| FR (1) | FR2471787A1 (enExample) |
| IT (1) | IT1144023B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS591417A (ja) * | 1982-06-28 | 1984-01-06 | Toyo Jozo Co Ltd | 持続性セフアレキシン錠およびその製造法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3137630A (en) * | 1961-06-09 | 1964-06-16 | Eastman Kodak Co | Process for preparing a dry, finely divided, gelatin particle product |
| GB1128275A (en) * | 1966-04-08 | 1968-09-25 | Jefferson Chem Co Inc | Method for the treatment of piperazine and salts thereof |
| SE421042B (sv) * | 1976-06-29 | 1981-11-23 | Kockums Chem | Sett att minska den for en viss biologisk effekt erforderliga mengden biologiskt aktiv substans |
-
1980
- 1980-12-19 FR FR8027032A patent/FR2471787A1/fr active Granted
- 1980-12-19 DE DE19803048039 patent/DE3048039A1/de not_active Withdrawn
- 1980-12-19 JP JP18118080A patent/JPS5699415A/ja active Pending
- 1980-12-19 IT IT50416/80A patent/IT1144023B/it active
- 1980-12-19 BE BE0/203254A patent/BE886778A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5699415A (en) | 1981-08-10 |
| FR2471787B1 (enExample) | 1984-05-18 |
| IT1144023B (it) | 1986-10-29 |
| IT8050416A0 (it) | 1980-12-19 |
| BE886778A (fr) | 1981-06-19 |
| FR2471787A1 (fr) | 1981-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69231965T2 (de) | Pharmazeutische formulierungen | |
| DE69110592T2 (de) | Pharmazeutische Zubereitung mit verbessertem Geschmack, poröse Partikel enthaltend, und deren Herstellungsmethode. | |
| EP0272265B1 (de) | Zerfallstablette und verfahren zu ihrer herstellung | |
| DE69925016T2 (de) | Verbesserte tablette mit schneller auflösbarkeit | |
| DE2357403C3 (de) | Kaugummi als Rauchwarenersatz | |
| DE69712332T2 (de) | Beta-lactam-antibiotikum enthaltende tabletten und verfahren zu deren herstellung | |
| DE69520768T2 (de) | Pharmazeutische Zubereitungen, die Fluoxetin enthalten | |
| DE3887179T2 (de) | Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung. | |
| DE60208673T2 (de) | Umhüllte pellets auf basis eines ace-hemmers | |
| DE69618934T2 (de) | Verbesserte organische zusammensetzungen | |
| DE68903431T2 (de) | Arzneistoff in kombination mit einem geschmacksueberdeckenden stoff und verfahren zu dessen herstellung. | |
| DE29824938U1 (de) | Pharmazeutische Zubereitung, die Clodronat als Wirkstoff und silifizierte mikrokristalline Cellulose als Exzipienten umfasst | |
| DE2816055A1 (de) | Neuer excipient und diesen enthaltende pharmazeutische zusammensetzung | |
| DE68903605T2 (de) | Kautablette. | |
| DE2224534B2 (de) | Pharmazeutisches praeparat mit langsamer wirkstoffabgabe | |
| EP0068191A2 (de) | Orale Dipyridamolformen | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| DE102007019071A1 (de) | Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin | |
| DE69518237T2 (de) | Feste pharmazeutische zubereitung mit (s)-2-(4-isobutylphenyl)propionsäure als wirkstoff und mikrokristalliner cellulose und kolloidalem silica als hilfstoff | |
| DE1292783B (de) | Verfahren zum Herstellen einer Tablette mit Depotwirkung | |
| DE3936112C2 (de) | Arzneimittelpräparate, die Piroxicam enthalten und Verfahren zu deren Herstellung | |
| DE3228999A1 (de) | Pharmazeutische zusammensetzungen mit verzoegerter wirkstofffreigabe | |
| DE69521275T2 (de) | Pharmazeutische Zubereitungen enthaltend Cefaclor | |
| DE4303846A1 (de) | Verfahren zur Herstellung einer S-Ibuprofen enthaltenden Tablette | |
| DE69101111T2 (de) | Oral anzuwendende Arzneimittel in Einzeldosisform. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |